Physician profile
Mohammad Imani
NPI 1134183643
$5,172.45
in general payments reported to CMS, 2019-2025
26 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $260 · 2021: $1,627 · 2022: $711 · 2023: $612 · 2024: $597 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,520.56 | 2019-2025 | Puraply, Via Matrix, Affinity |
| Treace Medical Concepts, INC. | $1,254.06 | 2021-2025 | |
| Smith+Nephew, INC. | $423.08 | 2020-2025 | Collagenase Santyl |
| Extremity Medical | $294.48 | 2022 | |
| Horizon Therapeutics Plc | $282.89 | 2019-2023 | Krystexxa |
| Amgen INC. | $252.91 | 2024-2025 | Krystexxa |
| Genzyme Corporation | $207.01 | 2025 | |
| Ethicon US, LLC | $141.03 | 2023 | Vistaseal, Harmonic |
| Stryker Corporation | $139.62 | 2021-2023 | Variax |
| Pacira Pharmaceuticals Incorporated | $115.12 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.72 | 2022-2023 | Lifevest |
| Ets Wound Care LLC | $60.41 | 2023 | |
| Paratek Pharmaceuticals, INC. | $57.31 | 2019-2023 | Nuzyra |
| Nevro Corp. | $55.93 | 2024 | Senza |
| Convatec INC. | $45.35 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $33.23 | 2025 | Yupelri |
| Integra Lifesciences Corporation | $32.59 | 2021 | |
| Heartflow, INC. | $28.94 | 2024 | |
| Kci USA, INC. | $27.08 | 2022 | |
| Averitas Pharma INC. | $24.77 | 2023 | Qutenza |
| Merck Sharp & Dohme LLC | $24.49 | 2024 | Capvaxive |
| Bioventus LLC | $23.30 | 2024 | Exogen Ultrasound Bone Healing System |
| Melinta Therapeutics, LLC | $22.03 | 2019 | |
| Insulet Corporation | $16.96 | 2025 | Omnipod |
| Zimmer Biomet Holdings, INC. | $13.16 | 2019 | |
| Abbott Laboratories | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Imani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.